查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970958

皮肤癌治疗市场－全球产业规模、份额、趋势、机会、预测：按疾病类型、治疗方法、地区和竞争格局划分，2021-2031年

Skin Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球皮肤癌治疗市场预计将从 2025 年的 68.9 亿美元成长到 2031 年的 105.1 亿美元，复合年增长率为 7.29%。

该市场涵盖多种药物疗法，例如化疗、标靶治疗和免疫疗法，用于治疗包括鳞状细胞癌、基底细胞癌和恶性黑色素瘤在内的恶性肿瘤。市场成长的主要驱动力是全球皮肤癌发生率的上升，这归因于人口老化和紫外线照射的增加。此外，诊断技术的进步使得疾病能够更早被发现，从而导致需要即时持续治疗的患者数量显着增加。

市场概览
预测期 2027-2031
市场规模：2025年 68.9亿美元
市场规模：2031年 105.1亿美元
复合年增长率：2026-2031年 7.29%
成长最快的细分市场 免疫疗法
最大的市场 北美洲

儘管有这些成长要素，但先进生物疗法的高昂成本常常阻碍市场扩张。这些成本限制了病患的就医途径，并加重了价格敏感地区的医疗预算负担。儘管疾病负担日益加重，但这一经济障碍仍然是新治疗方法广泛应用的主要阻碍。例如，美国癌症协会估计，到2024年，美国将新增约100,640例侵袭性黑色素瘤病例，凸显了迫切需要有效的治疗方案来应对这一日益严峻的健康挑战。

市场驱动因素

全球黑色素瘤和非黑色素瘤皮肤癌发生率的不断上升是推动全球皮肤癌治疗市场发展的主要动力。随着全球人口老化和紫外线辐射环境暴露的增加，诊断率持续上升，对稳定有效的药物治疗的需求也日益增长。患者负担的加重直接导致现有疗法的销售增加，同时也为新参与企业创造了市场机会。根据美国癌症协会发布的《2024年癌症事实与数据》，预计2024年美国将有约8,290人死于黑色素瘤，凸显了该疾病的高致死率以及延长患者生存期所需的强效治疗方案。

标靶药物递送技术和免疫疗法的快速发展推动了这一日益增长的需求。这些技术将治疗重点从安宁疗护转向根治性治疗，从而增强了市场提案。该领域的创新技术在后期临床试验中展现出显着成果，改善了临床疗效，并支撑了高额定价，从而实现了高利润。例如，默克在2024年2月报告称，受转移性疾病（包括黑色素瘤）领域强劲需求的推动，Keytruda在2023年的全球销售额增长了19%，达到250亿美元。此外，监管机构也对这些创新持正面态度。 2024年，Iovance Biotherapeutics宣布，FDA已加速核准Amtagvi上市，是第一个用于治疗固体癌肿瘤的细胞疗法。

市场挑战

先进生物治疗方法（包括免疫疗法和标靶治疗）的高昂成本是全球皮肤癌治疗市场成长的主要障碍。儘管这些治疗方法能够改善恶性肿瘤的临床疗效，但其高昂的价格对医疗预算造成压力，并限制了健保报销，尤其是在价格敏感地区。因此，严格的保险覆盖标准和高额的自付费用往往限制了患者获得这些治疗的机会。这种经济负担降低了新治疗方法的普及率，抑制了销售量，并阻碍了市场充分利用日益增长的有效皮肤癌治疗需求。

这种经济障碍造成了治疗方法与急需治疗的患者之间的差距，阻碍了市场有效减轻疾病负担的能力。目前，由于无法获得最佳治疗，死亡率居高不下，凸显了这个限制因素。根据美国癌症协会估计，到2025年，美国将有约8,430人死于黑色素瘤。这项统计数据表明，高昂的治疗费用限制了救命治疗的提供，从而造成了巨大的临床缺口，最终限制了收入潜力和全球市场扩张。

市场趋势

随着个人化mRNA癌症疫苗的商业化进程不断推进，治疗策略正发生显着转变，从现成的免疫疗法转向个人化新抗原疗法。这些治疗方法利用mRNA编码患者特异性突变，活化免疫系统，比单独使用抑制剂更有效清除癌细胞。近期数据显示，这些疗法具有生存优势，也支持了这项转变。默克在2024年6月发布的题为「Moderna和默克公布三年数据」的新闻稿中指出，在高危险群Pembrolizumab患者中，与Pembrolizumab单药联合治疗相比，mRNA-4157试验性疫苗合併帕博利珠单抗治疗可使復发或死亡风险降低49%。

同时，对于可切除的黑色素瘤，新辅助免疫疗法正逐渐兴起，治疗时机提前至术前。透过在术前使用双重查核点抑制剂，可以刺激肿瘤，诱导强烈的T细胞反应。与术后治疗通讯协定相比，这显着改善了治疗效果，同时也使临床医生能够评估病理反应。根据2024年6月在欧洲肿瘤内科学会（ESMO）年会上发表的数据，III期NADINA试验证实了该方法的有效性，新辅助辅助性治疗组的12个月无恶化存活期为83.7%，而术后辅助性治疗组为57.2%。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球皮肤癌治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 疾病类型（恶性黑色素瘤、非恶性黑色素瘤）
    • 治疗方法（化疗、免疫疗法、标靶治疗、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美皮肤癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲皮肤癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区皮肤癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲皮肤癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲皮肤癌治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球皮肤癌治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline PLC
  • Pfizer Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23980

The Global Skin Cancer Therapeutics Market is projected to expand from USD 6.89 Billion in 2025 to USD 10.51 Billion by 2031, reflecting a compound annual growth rate of 7.29%. This market encompasses various pharmaceutical interventions, such as chemotherapy, targeted therapy, and immunotherapy, designed to treat malignancies including squamous cell carcinoma, basal cell carcinoma, and melanoma. The market's growth is primarily fueled by the increasing global incidence of skin cancer, driven by an aging population and heightened exposure to ultraviolet radiation. Additionally, advancements in diagnostic capabilities have facilitated earlier disease detection, significantly enlarging the patient population that requires immediate and sustained therapeutic management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.89 Billion
Market Size 2031USD 10.51 Billion
CAGR 2026-20317.29%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Despite these growth drivers, market expansion is frequently hindered by the prohibitive costs of advanced biologic treatments, which restrict patient access and place a strain on healthcare budgets in price-sensitive regions. This financial barrier poses a substantial obstacle to the widespread adoption of newer therapies, even as the burden of disease increases. For instance, the American Cancer Society estimated that in 2024, approximately 100,640 new cases of invasive melanoma were diagnosed in the United States, highlighting the critical and urgent need for effective therapeutic solutions to address this growing health challenge.

Market Driver

The escalating global prevalence of melanoma and non-melanoma skin cancers acts as the fundamental driver for the Global Skin Cancer Therapeutics Market. As the global population ages and environmental exposure to ultraviolet radiation intensifies, diagnosis rates continue to rise, creating a need for a consistent supply of effective pharmaceutical interventions. This increasing patient burden leads directly to higher sales volumes for existing treatments and opens the market for new entrants. According to the American Cancer Society's 'Cancer Facts & Figures 2024', approximately 8,290 deaths from melanoma were projected to occur in the United States in 2024, underscoring the lethal nature of the disease and the imperative for potent therapeutic options that extend patient survival.

Complementing this volume-driven growth is the rapid advancement in targeted drug delivery and immunotherapy, which enhances the market's value proposition by shifting focus from palliative care to curative intent. Innovations in this sector have demonstrated remarkable success in late-stage trials, improving clinical outcomes and justifying premium pricing structures that bolster overall revenue. For example, Merck & Co. reported in February 2024 that worldwide sales of Keytruda increased by 19% to $25.0 billion in 2023, driven by strong demand in metastatic indications including melanoma. Furthermore, regulatory bodies are accommodating these innovations; in 2024, Iovance Biotherapeutics announced that the FDA granted accelerated approval for Amtagvi, the first cellular therapy indicated for a solid tumor malignancy.

Market Challenge

The substantial cost of advanced biologic treatments, including immunotherapies and targeted therapies, acts as a significant impediment to the growth of the Global Skin Cancer Therapeutics Market. While these interventions offer improved clinical outcomes for malignancies, they command premium prices that strain healthcare budgets and limit reimbursement coverage, particularly in regions sensitive to price. Consequently, strict insurance approval criteria and high out-of-pocket expenses often restrict patient access to these medications. This financial toxicity lowers adoption rates for newer therapies, thereby limiting sales volume and preventing the market from fully capitalizing on the rising demand for effective skin cancer management.

This economic barrier creates a disconnect between the availability of treatments and the patients who urgently require them, hampering the market's ability to effectively address the disease burden. The persistence of mortality rates, driven in part by limited access to optimal care, highlights this constraint. According to the American Cancer Society, an estimated 8,430 deaths are expected to be attributed to melanoma in the United States in 2025. This statistic underscores a significant clinical gap where the high cost of therapy restricts the delivery of life-saving care, ultimately constraining the revenue potential and expansion of the global market.

Market Trends

The increasing commercialization of personalized mRNA cancer vaccines marks a pivotal advancement, shifting from off-the-shelf immunotherapies to individualized neoantigen strategies. These therapies utilize mRNA to encode patient-specific mutations, priming the immune system to eliminate cancer cells more effectively than inhibitors alone, a shift supported by recent data showing superior survival rates. According to Merck & Co., in June 2024, the investigational vaccine mRNA-4157 combined with pembrolizumab reduced the risk of recurrence or death by 49% compared to pembrolizumab monotherapy in high-risk melanoma patients, as reported in their 'Moderna & Merck Announce 3-Year Data' release.

Simultaneously, the market is moving toward neoadjuvant immunotherapy for resectable melanoma, changing the timing of intervention to the preoperative setting. Administering dual checkpoint blockade before surgery leverages the tumor to generate a robust T-cell response, significantly improving outcomes compared to postoperative protocols while allowing clinicians to assess pathological response. According to the European Society for Medical Oncology in June 2024, the Phase 3 NADINA trial showed a 12-month event-free survival rate of 83.7% in the neoadjuvant group versus 57.2% for the adjuvant cohort, demonstrating the efficacy of this approach.

Key Market Players

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline PLC
  • Pfizer Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Report Scope

In this report, the Global Skin Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Skin Cancer Therapeutics Market, By Disease Type

  • Melanoma
  • Non-melanoma

Skin Cancer Therapeutics Market, By Treatment

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Others

Skin Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Skin Cancer Therapeutics Market.

Available Customizations:

Global Skin Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Skin Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Melanoma, Non-melanoma)
    • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Skin Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Treatment
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Skin Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Skin Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Skin Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Treatment

7. Europe Skin Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Treatment
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Skin Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Treatment
    • 7.3.2. France Skin Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Skin Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Skin Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Skin Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Treatment

8. Asia Pacific Skin Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Treatment
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Skin Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Treatment
    • 8.3.2. India Skin Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Treatment
    • 8.3.3. Japan Skin Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Skin Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Skin Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Treatment

9. Middle East & Africa Skin Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Treatment
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Skin Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Treatment
    • 9.3.2. UAE Skin Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Treatment
    • 9.3.3. South Africa Skin Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Treatment

10. South America Skin Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Treatment
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Skin Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Colombia Skin Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Treatment
    • 10.3.3. Argentina Skin Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Skin Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amgen Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Company
  • 15.3. Merck & Co., Inc.
  • 15.4. Sun Pharmaceutical Industries Ltd.
  • 15.5. Sanofi SA
  • 15.6. F. Hoffmann-La Roche Ltd.
  • 15.7. Glaxosmithkline PLC
  • 15.8. Pfizer Inc.
  • 15.9. Novartis AG
  • 15.10. Regeneron Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer